title: [The augmentation of tumor-specific immunity by T-T cell interaction].
abstract: The present study establishes a tumor-specific immunotherapy model based on the principle of T-T cell interaction mechanism responsible for augmenting the induction of anti-tumor-specific effector T cells. In this model, high incidence of tumor regression was observed in hosts bearing transplantable or autochthonous tumors when these hosts, in which hapten-reactive helper T cells had been generated, received an injection of haptenic solution into the growing tumor mass. This indicated a role of hapten-reactive helper T cells in regressing the tumor. In consideration clinical application of this tumor-specific immunotherapy model, we have also tried to investigate the use of more appropriate haptenic compounds and have succeeded in synthesizing a noble haptenic compound cross-reactive with BCG, a haptenic muramyl dipeptide (MDP) derivative. The results demonstrated that prepriming of BCG and subsequent immunization with syngeneic tumor cells (mitomycin C-treated) modified with the haptenic MDP derivative resulted in the enhanced induction of tumor-specific immunity. Further investigation is in progress to establish a new tumor-specific immunotherapy model by utilizing this haptenic MDP derivative.
authors.forename: H
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Y
authors.initials: Y
authors.lastname: Takai
authors.forename: M
authors.initials: M
authors.lastname: Fukuzawa
authors.forename: T
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Y
authors.initials: Y
authors.lastname: Izumi
authors.forename: Y
authors.initials: Y
authors.lastname: Mizushima
authors.forename: J
authors.initials: J
authors.lastname: Qian
authors.forename: M
authors.initials: M
authors.lastname: Ogata
authors.forename: A
authors.initials: A
authors.lastname: Kosugi
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology; D002450:Cell Communication; D003429:Cross Reactions; D006241:Haptens; D006649:Histocompatibility Antigens / Q000276:immunology; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D006241:Haptens; D006649:Histocompatibility Antigens; D008937:Mitomycins; C029237:tumor-associated transplantation antigen; D016685:Mitomycin